The Pharmasyntez group is to launch manufacturing of a full range of dialysis products at its new facility in Kaluga
The Pharmasyntez Group, one of the leading biopharmaceutical companies, announces plans to launch production of a full range of medical products for dialysis at its new Pharmasyntez-Medtech facility in Kaluga starting in 2025.
The Pharmasyntez Group, one of the leading biopharmaceutical companies, announces plans to launch production of a full range of medical products for dialysis at its new Pharmasyntez-Medtech facility in Kaluga starting in 2025.
Up until 2023, over 90% of all medical and pharmaceutical products required for dialysis had been manufactured strictly outside the Russian Federation. In 2023–2024, the Pharmasyntez Group undertook an unprecedented effort by successfully introducing TM 'DiaSolution' and 'DiaSolution PD' products to the market, sequentially closing the emerging deficit in solutions for peritoneal dialysis. This was the first example of comprehensive import substitution to provide Russian patients with high-quality domestic products for dialysis.
Chronic kidney disease is a socially significant disease: it is included in the list of 20 major “killer diseases” of mankind. In the terminal stage of this disease, patients require daily renal replacement therapy, the main types of which can be kidney transplantation or dialysis. In 2023, more than 64,000 people in Russia were receiving renal replacement therapy, the need for which is only growing every year.
Vikram Punia, President of the Pharmasyntez Group, states: “Today, due to the complicated geopolitical situation, it is especially important to ensure drug safety for patients with socially significant diseases. One of the priorities of the Pharmasyntez Group production development is the launch of comprehensive provision of Russian patients with quality products for all types of dialysis. We are now preparing to produce the first domestic medical products for peritoneal dialysis at our new facility in Kaluga in 2025. This is our contribution to the development of modern home dialysis methods in Russia. Our immediate plans include the production of a full range of products for chronic hemodialysis and extracorporeal hemocorrection.”
Over the past few years, when discussing ways of development of renal replacement therapy in Russia, special emphasis has been placed on increasing the number of transplanted kidney patients and patients receiving peritoneal dialysis, which is the only type of home dialysis available in our country. Development of comprehensive import substitution of medical and pharmaceutical products for all types of dialysis is an important step in building drug safety for Russian patients and providing access to the most advanced treatment methods.
Nikolay Panikarovsky, the Director General at Pharmasyntez-Medtech, LLC noted: “Now Pharmasyntez-Medtech is at the stage of launching a new project for import-substituting production of medical devices for dialysis. The first stage of the project will be the launch of consumables and medical equipment manufacturing for automated and continuous ambulatory peritoneal dialysis under the NOVADIAL brand. The production capacity of Pharmasyntez-Medtech will allow us to cover the entire demand for these products in the country. We are also working on dialysis solutions development, dialyzers, delivery lines, and domestically produced concentrates.”
The Pharmasyntez Group, one of the leading biopharmaceutical companies, announces plans to launch production of a full range of medical products for dialysis at its new Pharmasyntez-Medtech facility in Kaluga starting in 2025.
The Pharmasyntez Group, one of the leading biopharmaceutical companies, announces plans to launch production of a full range of medical products for dialysis at its new Pharmasyntez-Medtech facility in Kaluga starting in 2025.
Up until 2023, over 90% of all medical and pharmaceutical products required for dialysis had been manufactured strictly outside the Russian Federation. In 2023–2024, the Pharmasyntez Group undertook an unprecedented effort by successfully introducing TM 'DiaSolution' and 'DiaSolution PD' products to the market, sequentially closing the emerging deficit in solutions for peritoneal dialysis. This was the first example of comprehensive import substitution to provide Russian patients with high-quality domestic products for dialysis.
Chronic kidney disease is a socially significant disease: it is included in the list of 20 major “killer diseases” of mankind. In the terminal stage of this disease, patients require daily renal replacement therapy, the main types of which can be kidney transplantation or dialysis. In 2023, more than 64,000 people in Russia were receiving renal replacement therapy, the need for which is only growing every year.
Vikram Punia, President of the Pharmasyntez Group, states: “Today, due to the complicated geopolitical situation, it is especially important to ensure drug safety for patients with socially significant diseases. One of the priorities of the Pharmasyntez Group production development is the launch of comprehensive provision of Russian patients with quality products for all types of dialysis. We are now preparing to produce the first domestic medical products for peritoneal dialysis at our new facility in Kaluga in 2025. This is our contribution to the development of modern home dialysis methods in Russia. Our immediate plans include the production of a full range of products for chronic hemodialysis and extracorporeal hemocorrection.”
Over the past few years, when discussing ways of development of renal replacement therapy in Russia, special emphasis has been placed on increasing the number of transplanted kidney patients and patients receiving peritoneal dialysis, which is the only type of home dialysis available in our country. Development of comprehensive import substitution of medical and pharmaceutical products for all types of dialysis is an important step in building drug safety for Russian patients and providing access to the most advanced treatment methods.
Nikolay Panikarovsky, the Director General at Pharmasyntez-Medtech, LLC noted: “Now Pharmasyntez-Medtech is at the stage of launching a new project for import-substituting production of medical devices for dialysis. The first stage of the project will be the launch of consumables and medical equipment manufacturing for automated and continuous ambulatory peritoneal dialysis under the NOVADIAL brand. The production capacity of Pharmasyntez-Medtech will allow us to cover the entire demand for these products in the country. We are also working on dialysis solutions development, dialyzers, delivery lines, and domestically produced concentrates.”